1. Signaling Pathways
  2. Metabolic Enzyme/Protease
    NF-κB
  3. MALT1

MALT1

mucosa associated lymphoid tissue lymphoma translocation gene 1

MALT1 is a paracaspase, which is related to the caspase (cysteine-aspartic proteases) family of proteases but cleaves after Arg residues instead of Asp. MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. MALT1 is a unique paracaspase protein that transduces aberrant oncogenic signaling in ABC-DLBCL. MALT1 represents a potentially important therapeutic target for ABC-DLBCL and MALT lymphoma. MALT1 small molecule inhibitors might be useful chemical tools for studying MALT1 biology and treating MALT1-addicted tumors.

MALT1 Related Products (22):

Cat. No. Product Name Effect Purity
  • HY-115466
    MLT-748
    Inhibitor 99.90%
    MLT-748 is a potent, selective and allosteric inhibitor of MALT1, binds MALT1 in the allosteric Trp580 pocket, with an IC50 of 5 nM.
  • HY-12276
    MALT1 inhibitor MI-2
    Inhibitor 99.88%
    MALT1 inhibitor MI-2 is a MALT1 inhibitor (IC50=5.84 μM). MALT1 inhibitor MI-2 binds directly to MALT1, irreversibly suppresses protease function and is accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. MALT1 inhibitor MI-2 shows nontoxic to animals.
  • HY-121282A
    Mepazine hydrochloride
    Inhibitor 98.29%
    Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective MALT1 protease inhibitor with IC50s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine hydrochloride affects viability of ABC-DLBCL cells by enhancing apoptosis.
  • HY-139399
    Safimaltib
    Inhibitor 99.89%
    Safimaltib (JNJ-67856633) is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. Safimaltib in some cases lead to tumor stasis.
  • HY-134820
    MLT-943
    Inhibitor 99.71%
    MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC50 across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood). MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research.
  • HY-143427
    MALT1-IN-9
    Inhibitor
    MALT1-IN-9 is a potent MALT1 protease inhibitor with a IC50 of <500 nM in Raji MALT1-GloSensor cells. MALT1-IN-9 has anticancer effects (WO2021000855A1; Compound 5).
  • HY-143423
    MALT1-IN-5
    Inhibitor
    MALT1-IN-5 (compound 1) is a potent MALT1 protease inhibitor. MALT1-IN-5 can be used for cancer research.
  • HY-143422
    MALT1-IN-3
    Inhibitor
    MALT1-IN-3 (compound 122) is a potent MALT1 protease inhibitor, with an IC50 of 0.06 μM. MALT1-IN-3 has IC50 of 0.14 and 0.13 μM for human IL6/IL10 in OCI-LY3 cells, respectively.
  • HY-131902
    MLT-231
    Inhibitor 99.55%
    MLT-231 is a potent, highly selective allosteric MALT1 Inhibitor with an IC50 of 9 nM. MLT-231 specifically prevents endogenous BCL10 cleavage with IC50 of 160 nM. MLT-231 shows antitumor activity in an ABC-DLBCL type xenograft model in mouse.
  • HY-P1407
    Z-VRPR-FMK TFA
    Inhibitor
    Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection.
  • HY-121282
    Mepazine
    Inhibitor
    Mepazine (Pecazine) is a potent and selective MALT1 protease inhibitor with IC50s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosis.
  • HY-124587
    MLT-747
    Inhibitor
    MLT-747 is a potent, selective, allosteric inhibitor of MALT1, binds MALT1 in the allosteric Trp580 pocket, with an IC50 of 14 nM.
  • HY-142648
    MLT-985
    Inhibitor
    MLT-985 is a highly selective allosteric MALT1 inhibitor with an IC50 value of 3 nM.
  • HY-143425A
    (R)-MALT1-IN-7
    Inhibitor
    (R)-MALT1-IN-7 (compound 142a) is a potent MALT1 protease inhibitor. (R)-MALT1-IN-7 has the potential for cancer research.
  • HY-142648A
    (R)-MLT-985
    Inhibitor
    (R)-MLT-985 (compound 11) is a potent MALT1 protease inhibitor with an IC50 of 3 nM. (R)-MLT-985 has an IC50 of 20 nM for MALT1-dependent IL-2 production in Jurkat cells. (R)-MLT-985 suppresses growth and aberrant CARD11/BCL10/MALT1 complex signaling in ABC-DLBCL cells.
  • HY-148249
    NVS-MALT1
    Inhibitor
    NVS-MALT1 is a MALT1 allosteric inhibitor.
  • HY-143423A
    (S)-MALT1-IN-5
    Inhibitor
    (S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1).
  • HY-143426
    MALT1-IN-8
    Inhibitor
    MALT1-IN-8 is a potent MALT1 protease inhibitor with a IC50 of 2 nM. MALT1-IN-8 inhibits the growth of OCI-LY3 lymphoma cells with an IC50 of 1.16 μM. MALT1-IN-8 has anticancer effects (WO2018165385A1; Compound 8).
  • HY-143422A
    (R)-MALT1-IN-3
    Inhibitor
    (R)-MALT1-IN-3 (compound 121) is a potent MALT1 protease inhibitor with an IC50 of 20 nM. (R)-MALT1-IN-3 has IC50 of 60 nM, 40 nM for human IL6/IL10 in OCI-LY3 cells, respectively.
  • HY-143424
    MALT1-IN-6
    Inhibitor
    MALT1-IN-6 is a potent MALT1 protease inhibitor with a Ki of 9 nM. MALT1-IN-6 has anticancer effects (WO2018226150A1; Compound 4).